Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AGRX
- CUSIP: N/A
- Web: www.agiletherapeutics.com
Capitalization:- Market Cap: $115.51 million
- Outstanding Shares: 28,806,000
Average Prices:- 50 Day Moving Avg: $3.49
- 200 Day Moving Avg: $3.49
- 52 Week Range: $1.82 - $7.95
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.66
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.01 per share
- Price / Book: 3.97
Profitability:- EBIDTA: ($29,000,000.00)
- Return on Equity: -80.80%
- Return on Assets: -52.88%
Debt:- Debt-to-Equity Ratio: 0.27%
- Current Ratio: 3.37%
- Quick Ratio: 3.37%
Misc:- Average Volume: 293,072 shs.
- Beta: 1.93
- Short Ratio: 5.96
Frequently Asked Questions for Agile Therapeutics (NASDAQ:AGRX)
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics, Inc. (NASDAQ:AGRX) released its quarterly earnings results on Friday, July, 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.02. During the same quarter in the prior year, the firm earned ($0.29) EPS. View Agile Therapeutics' Earnings History.
Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2017?
6 brokerages have issued 1 year target prices for Agile Therapeutics' stock. Their forecasts range from $8.00 to $13.00. On average, they anticipate Agile Therapeutics' share price to reach $10.20 in the next year. View Analyst Ratings for Agile Therapeutics.
What are analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Do-over should position Twirla for regulatory success. Results of the SECURE Phase 3 trial support FDA approval, in our opinion. A PDUFA date of December 26, may provide trading-oriented investors with an attractive end- of-year opportunity." (9/21/2017)
- 2. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (3/13/2017)
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a decline in short interest in the month of August. As of August 15th, there was short interest totalling 555,487 shares, a decline of 48.1% from the July 31st total of 1,070,592 shares. Based on an average trading volume of 554,541 shares, the days-to-cover ratio is presently 1.0 days. Approximately 4.1% of the shares of the stock are short sold.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include ObsEva SA (OBSV), Faron Pharmaceuticals Oy (FARN), Clearside Biomedical (CLSD), OVID THERAPEUTC (OVID), MannKind Corporation (MNKD), OncoCyte Corp (OCX), Vital Therapies (VTL), Catalyst Pharmaceuticals (CPRX), Kindred Biosciences (KIN), Foamix Pharmaceuticals (FOMX), Zymeworks (ZYME), Cascadian Therapeutics (CASC), Spring Bank Pharmaceuticals (SBPH), vTv Therapeutics (VTVT), Aileron Therapeutics (ALRN), Verastem (VSTM), Threshold Pharmaceuticals (MTEM) and Fate Therapeutics (FATE).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Alfred Altomari, Chairman of the Board, President, Chief Executive Officer
- Scott M. Coiante, Chief Financial Officer, Vice President
- Elizabeth Garner M.D., Senior Vice President, Chief Medical Officer
- Renee Selman, Chief Commercial Officer
- Abhijeet J. Lele, Lead Independent Director
- John W. Hubbard Ph.D., Director
- Ajit S. Shetty Ph.D., Director
- James Patrick Tursi M.D., Director
- Seth H. Z. Fischer, Independent Director
Who owns Agile Therapeutics stock?
Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Investor AB (12.19%), Franklin Resources Inc. (9.62%),
CAXTON CORP
(5.30%),
CAXTON CORP
(4.80%), Caxton Corp (5.64%) and Vivo Capital LLC (5.26%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Jay Moorin and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?
Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?
Agile Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, LMR Partners LLP, Susquehanna International Group LLP, Janney Montgomery Scott LLC, Royal Bank of Canada and Royce & Associates LP. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Jay Moorin and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.
How do I buy Agile Therapeutics stock?
Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of Agile Therapeutics stock can currently be purchased for approximately $4.01.
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Agile Therapeutics (NASDAQ:AGRX)Earnings History by Quarter for Agile Therapeutics (NASDAQ AGRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/28/2017 | Q2 2017 | ($0.28) | ($0.26) | | | View | N/A |  |
| 3/8/2017 | Q4 2016 | ($0.28) | ($0.29) | | | View | N/A | |
| 11/7/2016 | Q3 | ($0.35) | ($0.27) | | | View | N/A | |
| 8/8/2016 | Q2 | ($0.29) | ($0.29) | | | View | N/A | |
| 5/9/2016 | Q1 | ($0.38) | ($0.27) | | | View | N/A | |
| 11/9/2015 | Q3 2015 | ($0.42) | ($0.42) | | | View | N/A | |
| 8/13/2015 | Q2 2015 | ($0.37) | ($0.38) | | | View | N/A | |
| 5/12/2015 | Q1 2015 | ($0.35) | ($0.35) | | | View | N/A | |
| 3/26/2015 | Q4 2014 | ($0.40) | ($0.37) | | | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.50) | ($0.34) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Agile Therapeutics (NASDAQ:AGRX)2017 EPS Consensus Estimate: ($1.14)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.30) | ($0.30) | ($0.30) |
| Q2 2017 | 3 | ($0.30) | ($0.25) | ($0.28) |
| Q3 2017 | 3 | ($0.30) | ($0.26) | ($0.27) |
| Q4 2017 | 3 | ($0.37) | ($0.25) | ($0.29) |
(Data provided by Zacks Investment Research)
Dividend History for Agile Therapeutics (NASDAQ:AGRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Agile Therapeutics (NASDAQ:AGRX)Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 67.59%
Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/25/2017 | Alfred Altomari | Chairman | Buy | 10,000 | $3.34 | $33,400.00 | |
| 8/25/2017 | Renee Selman | Insider | Buy | 7,250 | $3.35 | $24,287.50 | |
| 5/11/2017 | Alfred Altomari | Chairman | Buy | 10,000 | $3.51 | $35,100.00 | |
| 5/11/2017 | Renee Selman | Insider | Buy | 53,333 | $3.68 | $196,265.44 | |
| 1/27/2016 | Jay Moorin | Major Shareholder | Buy | 393,700 | $6.35 | $2,499,995.00 | |
| 6/2/2015 | Alfred Altomari | CEO | Buy | 2,500 | $8.73 | $21,825.00 | |
| 1/23/2015 | Jay Moorin | Major Shareholder | Buy | 811,966 | $5.85 | $4,750,001.10 | |
| 5/29/2014 | Care Capital Iii Llc | Major Shareholder | Buy | 500,000 | $6.00 | $3,000,000.00 | |
| 5/23/2014 | Andrew N Schiff | Director | Buy | 1,333,333 | $6.00 | $7,999,998.00 | |
| 5/22/2014 | Ab Investor | Major Shareholder | Buy | 1,000,000 | $6.00 | $6,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Agile Therapeutics (NASDAQ:AGRX)
Latest Headlines for Agile Therapeutics (NASDAQ:AGRX)
| Source: |
|
| Date | Headline |
|---|
 | Agile Therapeutics, Inc. (AGRX) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 21 at 5:38 PM |
| Analyzing Agile Therapeutics (AGRX) and Intra-Cellular Therapies (ITCI)
www.americanbankingnews.com - September 20 at 6:08 PM |
| Head to Head Analysis: Agile Therapeutics (AGRX) vs. Its Competitors
www.americanbankingnews.com - September 20 at 4:28 AM |
| Agile Therapeutics, Inc. (AGRX) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - September 16 at 4:22 AM |
 | Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 14 at 3:46 PM |
 | Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 3:46 PM |
| Agile Therapeutics, Inc. (AGRX) Price Target Increased to $10.00 by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 9:35 AM |
 | Agile Therapeutics (AGRX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 4:42 PM |
 | Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for ... - Nasdaq
www.nasdaq.com - September 9 at 3:28 PM |
| Agile Therapeutics (AGRX) Presents At 6th Annual Liolios Gateway Conference - Slideshow
seekingalpha.com - September 8 at 3:58 PM |
| Agile Therapeutics, Inc. (AGRX) Earns Buy Rating from Janney Montgomery Scott
www.americanbankingnews.com - September 7 at 10:08 PM |
| Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for ... - GlobeNewswire (press release)
globenewswire.com - September 7 at 3:32 PM |
| Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine
finance.yahoo.com - September 7 at 3:32 PM |
| Agile Therapeutics, Inc. (AGRX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 6 at 6:40 AM |
| Agile Therapeutics: Is This ~$3.50 'Busted IPO' Worthy Of Investment Consideration? - Seeking Alpha
seekingalpha.com - September 5 at 9:40 PM |
| ValuEngine Downgrades Agile Therapeutics, Inc. (AGRX) to Strong Sell
www.americanbankingnews.com - September 3 at 11:22 PM |
| Agile Therapeutics, Inc. (AGRX) Chairman Alfred Altomari Buys 10,000 Shares
www.americanbankingnews.com - August 28 at 8:02 PM |
| Renee Selman Buys 7,250 Shares of Agile Therapeutics, Inc. (AGRX) Stock
www.americanbankingnews.com - August 28 at 8:02 PM |
| Zacks: Brokerages Anticipate Agile Therapeutics, Inc. (AGRX) to Announce -$0.25 EPS
www.americanbankingnews.com - August 28 at 4:18 PM |
| Agile Therapeutics, Inc. (AGRX) Short Interest Update
www.americanbankingnews.com - August 28 at 1:20 AM |
| Agile Therapeutics, Inc. (AGRX) Given Buy Rating at Janney Montgomery Scott
www.americanbankingnews.com - August 24 at 8:52 PM |
| Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference - GlobeNewswire (press release)
globenewswire.com - August 16 at 8:35 PM |
| Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference
finance.yahoo.com - August 16 at 8:35 PM |
| Agile Therapeutics, Inc. (NASDAQ:AGRX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 12 at 6:50 AM |
| AGRX: Raises $18.3 Million in Public Offering
finance.yahoo.com - August 10 at 10:06 PM |
 | Agile Therapeutics (AGRX) Plans Offering of Common Stock
www.streetinsider.com - August 3 at 9:45 PM |
| Health Care Sector Update for 08/03/2017: AGRX,OSUR,CHRM - Nasdaq
www.nasdaq.com - August 3 at 4:43 PM |
 | Mid-Morning Market Update: Markets Mostly Lower; Kellogg Beats Q2 Expectations - Benzinga
www.benzinga.com - August 3 at 4:43 PM |
| Agile Therapeutics (AGRX) Prices 5.33M Common Stock Offering at $3.75/Share - StreetInsider.com
www.streetinsider.com - August 3 at 4:43 PM |
| Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
finance.yahoo.com - August 3 at 4:42 PM |
| Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
finance.yahoo.com - August 3 at 4:42 PM |
| Agile Therapeutics Tanks on Secondary Offering
finance.yahoo.com - August 3 at 4:42 PM |
| Agile Therapeutics Tanks on Secondary Offering
finance.yahoo.com - August 3 at 4:42 PM |
| Agile Therapeutics (AGRX) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - August 2 at 8:33 PM |
| Agile Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - August 2 at 8:33 PM |
| Q3 2017 EPS Estimates for Agile Therapeutics, Inc. (NASDAQ:AGRX) Increased by William Blair
www.americanbankingnews.com - August 2 at 7:48 AM |
| Research Analysts Offer Predictions for Agile Therapeutics, Inc.'s Q3 2017 Earnings (AGRX)
www.americanbankingnews.com - August 2 at 7:48 AM |
| AGRX: NDA for Twirla® Accepted by FDA; PDUFA is Dec. 26, 2017
finance.yahoo.com - July 31 at 3:46 PM |
| AGRX: NDA for Twirla® Accepted by FDA; PDUFA is Dec. 26, 2017
finance.yahoo.com - July 31 at 3:46 PM |
| Agile Therapeutics, Inc. (NASDAQ:AGRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 11:40 AM |
| Agile Therapeutics, Inc. (AGRX) Releases Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - July 29 at 1:53 PM |
| BUZZ-US STOCKS ON THE MOVE-Western Digital, Boston Beer, Newater - Nasdaq
www.nasdaq.com - July 28 at 3:58 PM |
| Agile Therapeutics Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - July 28 at 3:58 PM |
| Agile Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 28 at 3:58 PM |
| Agile Therapeutics reports 2Q loss
finance.yahoo.com - July 28 at 3:58 PM |
| After-Hours Movers 07/27: (SAM) (FSLR) (BIDU) Higher; (ELLI) (NUVA) (AMZN) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 27 at 8:51 PM |
| Agile Therapeutics (AGRX) Announces FDA Acceptance of the NDA Resubmission of Twirla - StreetInsider.com
www.streetinsider.com - July 27 at 8:51 PM |
| Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
finance.yahoo.com - July 27 at 8:51 PM |
| Analysts Anticipate Agile Therapeutics, Inc. (NASDAQ:AGRX) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - July 21 at 12:05 AM |
| Corium Presents Clinical Results from Pilot Bioequivalence Study of Corplex™ Donepezil Transdermal
www.nasdaq.com - July 19 at 4:35 PM |
Agile Therapeutics (AGRX) Chart for Monday, September, 25, 2017
